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RESEARCH Open Access
Azithromycin drives alternative
macrophage activation and improves
recovery and tissue sparing in contusion
spinal cord injury
Bei Zhang1†, William M. Bailey1†, Timothy J. Kopper1,2, Michael B. Orr1,2, David J. Feola3 and John C. Gensel1,4*
Abstract
Background: Macrophages persist indefinitely at sites of spinal cord injury (SCI) and contribute to both
pathological and reparative processes. While the alternative, anti-inflammatory (M2) phenotype is believed to
promote cell protection, regeneration, and plasticity, pro-inflammatory (M1) macrophages persist after SCI and
contribute to protracted cell and tissue loss. Thus, identifying non-invasive, clinically viable, pharmacological
therapies for altering macrophage phenotype is a challenging, yet promising, approach for treating SCI.
Azithromycin (AZM), a commonly used macrolide antibiotic, drives anti-inflammatory macrophage activation in
rodent models of inflammation and in humans with cystic fibrosis.
Methods: We hypothesized that AZM treatment can alter the macrophage response to SCI and reduce progressive
tissue pathology. To test this hypothesis, mice (C57BL/6J, 3-month-old) received daily doses of AZM (160 mg/kg) or
vehicle treatment via oral gavage for 3 days prior and up to 7 days after a moderate-severe thoracic contusion SCI
(75-kdyn force injury). Fluorescent-activated cell sorting was used in combination with real-time PCR (rtPCR) to
evaluate the disposition and activation status of microglia, monocytes, and neutrophils, as well as macrophage
phenotype in response to AZM treatment. An open-field locomotor rating scale (Basso Mouse Scale) and gridwalk
task were used to determine the effects of AZM treatment on SCI recovery. Bone marrow-derived macrophages
(BMDMs) were used to determine the effect of AZM treatment on macrophage phenotype in vitro.
Results: In accordance with our hypothesis, SCI mice exhibited significantly increased anti-inflammatory and
decreased pro-inflammatory macrophage activation in response to AZM treatment. In addition, AZM treatment led
to improved tissue sparing and recovery of gross and coordinated locomotor function. Furthermore, AZM treatment
altered macrophage phenotype in vitro and lowered the neurotoxic potential of pro-inflammatory, M1 macrophages.
Conclusions: Taken together, these data suggest that pharmacologically intervening with AZM can alter SCI
macrophage polarization toward a beneficial phenotype that, in turn, may potentially limit secondary injury processes.
Given that pro-inflammatory macrophage activation is a hallmark of many neurological pathologies and that AZM is
non-invasive and clinically viable, these data highlight a novel approach for treating SCI and other maladaptive
neuroinflammatory conditions.
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Background
Spinal cord injury (SCI) triggers a CNS macrophage
response consisting of pro-inflammatory, classically acti-
vated cells and anti-inflammatory, alternatively activated
cells [1, 2]. Pro-inflammatory macrophages are neuro-
toxic, while anti-inflammatory macrophages promote
axon growth and remyelination without concurrent
neurotoxicity. Unfortunately, macrophages are polarized
toward a pro-inflammatory phenotype after human and
rodent SCI [1–4], and it is believed that these cells con-
tribute to secondary injury processes. Indeed, TNF-α,
iron, or age-related shifts toward pro-inflammatory
macrophages are detrimental for SCI recovery [5–7].
In contrast, increasing anti-inflammatory macrophage
activation through transplantation, adoptive transfer,
or selective monocyte recruitment improves functional
recovery [8–10]. These approaches illustrate the
therapeutic potential of altering macrophage pheno-
types on SCI recovery and repair; however, as a field,
we are challenged to identify non-invasive, clinically
viable, pharmacological techniques for altering SCI
macrophage activation.
Macrophages are plastic and can adopt dynamic
phenotypic and functional properties in response to new
stimuli [11]. The pro-inflammatory SCI environment po-
tentiates a pathological macrophage phenotype [3, 6].
However, through pharmacological interventions, it is
possible to alter the way macrophages respond to pro-
inflammatory stimuli. Azithromycin (AZM) is a macro-
lide antibiotic commonly used to treat infections in SCI
individuals [12, 13]. In addition to its antibiotic proper-
ties, AZM increases alternative macrophage activation in
rodent models of lung infection, skin inflammation, and
sepsis; in alveolar macrophage and human monocyte
cultures when incubated with pro-inflammatory stimu-
lants; and in humans with cystic fibrosis [14–21]. Specific-
ally, we previously observed that macrophages activated
with pro-inflammatory stimuli adopt an anti-inflammatory
phenotype in the presence of AZM [14]. Despite its
reported immunomodulatory effects and safe pharmaco-
logical properties, the neurotherapeutic potential of alter-
ing macrophage activation with AZM in CNS disorders
and trauma has not been examined.
In the present study, we used AZM to increase
pro-reparative, alternative macrophage activation in
the injured mouse spinal cord. In vivo, AZM signifi-
cantly increased gene expression indicative of anti-
inflammatory macrophage activation and reduced macro-
phage pro-inflammation gene expression. AZM treatment
resulted in significantly increased functional recovery and
less long-term tissue damage. In vitro, AZM drove
anti-inflammatory cytokine production in response
pro-inflammatory stimuli and rendered pro-inflammatory
macrophages non-toxic. Collectively, these data illustrate
the therapeutic potential of pharmacologically manipulat-
ing macrophages in SCI and identify AZM as a novel tool




Mice were treated with AZM (160 mg/kg/day) or vehicle
for 3 days prior to a moderate-severe contusion SCI.
Drug administration was continued daily up to 7 days
post injury (dpi). At 1, 3, and 7 dpi, n = 3–5 animals/
treatment group were sacrificed and spinal cord tissue
harvested for cell phenotypic analysis using fluorescent-
activated cell sorting (FACS). Cells sorted from 3 and
7 dpi were further phenotypically evaluated using quan-
titative real-time PCR (rtPCR). Locomotor analyses
(Basso Mouse Scale (BMS) and gridwalk) were con-
ducted on a separate set of animals (n = 8–10/group)
over the course of 4 weeks. At 28 dpi, these animals
were sacrificed and spinal cord sections generated for
histological analyses of tissue sparing and macrophage
phenotype. In vitro studies were conducted using bone
marrow-derived macrophages (BMDM) from adult mice.
BMDMs were stimulated with AZM and/or pro-
inflammatory stimuli (LPS + interferon-gamma (INFγ)).
Control cells were left unstimulated. Secreted interleukin
(IL)-10 and IL-12 levels were determined in the BMDM
supernatant through ELISA analysis. The neurotoxicity
of the BMDM supernatants was determined using the
MTT assay to quantify the viability of supernatant-
treated Neuro-2a cells.
Animals
Experiments were performed using 4-month-old female
C57BL/6 mice (Jackson Laboratory, Bar Harbor, Maine).
Animals were housed in IVC cages with ad libitum access
to food and water. All procedures were performed in ac-
cordance with the guidelines and protocols of the Office
of Research Integrity and with approval of the Institutional
Animal Care and Use Committee at the University of
Kentucky.
Spinal cord injury
Animals were anesthetized via intraperitoneal (i.p.) injec-
tions of ketamine (100 mg/kg) and xylazine (10 mg/kg).
Following a T9 laminectomy, a moderate-severe thoracic
SCI was produced using the Infinite Horizon (IH) injury
device (75-kdyn displacement; Precision Systems and
Instrumentation) [22]. Any animals receiving SCI with
abnormalities in the force vs. time curve generated by
the IH device were excluded from analysis. These abnor-
malities are indicative of bone hits or instability in the
spinal cord at the time of injury and occurred <10 % of
the time. Mice receiving a laminectomy without injury
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were used as sham controls. After injury, muscle and
skin incisions were closed using monofilament suture.
Post surgically, animals received one subcutaneous injec-
tion of buprenorphine-SR (1 mg/kg) and antibiotic
(5 mg/kg, enroloxacin 2.27 %: Norbrook Inc., Lenexa,
KS) in 2 ml of saline and were housed in warming cages
overnight. Animals continued to receive antibiotic sub-
cutaneously in 1 ml saline for 5 days. Azithromycin
(160 mg/kg) or vehicle (1 % methylcellulose) was deliv-
ered in 0.1-ml volume via oral gavage daily beginning
3 days prior and continuing for 7 days post injury. Food
and water intake and the incision site were monitored
throughout the course of the study. Bladder expression
was performed on injured mice twice daily.
Cell isolation and phenotyping for flow cytometry
Following i.p. injection of ketamine (120 mg/kg) and
xylazine (10 mg/kg), mice were transcardially perfused
with ice cold diethyl pyrocarbonate phosphate-buffered
saline (DEPC-PBS) then 1 cm of spinal cord centered on
the injury site was rapidly dissected and placed in ice
cold DEPC-PBS. The tissue was dissociated on ice using
a size 40 mesh cell dissociation kit (Sigma, S0770) and
rinsed twice with PBS. The dissociated tissue was then
passed through a 70-μm screen filter (BD:352350). Cells
were centrifuged at 200×g for 10 min at 4 °C, resus-
pended in fetal bovine serum (FBS) staining buffer (BD:
554656), and then cell numbers for each animal acquired
using a hemocytometer. Cells were incubated with Fc
block (BD:553142) for 15 min on ice and then were in-
cubated with CD11b-APC, GR1-PE-Cy7, CD45-PerCP-
Cy5.5, and CD206 (mannose receptor)-PE antibodies
(BD Biosciences) as previously described [17]. Cell were
washed twice with FBS staining buffer and resuspended
in appropriate volumes of FBS staining buffer for
fluorescent-activated cell sorting (FACS) analysis. Ex-
pression of these surface receptors was determined using
an iCyt Synergy sorter system (Sony) in the UK Flow Cy-
tometry Core Facility. Microglia, macrophages, and neu-
trophils were identified by CD11b+/CD45lo/GR1lo/neg,
CD11b+/CD45hi/GR1lo/neg, and CD11b+/CD45hi/GR1hi
expressions, respectively [5, 6]. CD206 expression levels
were used to determine M2-polarization states. For each
antibody, gating was determined based upon appropriate
negative isotype-stained controls. Flow data were ana-
lyzed using FlowJo software (Tree Star). Cell numbers
for each animal were estimated from cell percentages
and hemocytometer counts. All investigators involved in
the flow/FACS analyses have been certified for flow
research methods and applications through the com-
pletion of the Annual Course in Cytometry sponsored
by the Cytometry Education Association and Verity
Software House.
Gene expression from FACS-sorted cells
All FACS-sorted macrophages (CD11b+/CD45lo/hi/
GR1lo/neg), which consisted of both microglia- and
monocyte-macrophages, were collected in FBS staining
buffer (BD:554656), and 0.75 ml TRIzol LS reagent (Life
Technologies) was added per 0.25 ml of suspension.
Total RNA was isolated based on the manufacturer’s
protocol, with an additional phase separation using BCP,
precipitation with isopropanol (Sigma-Aldrich, St. Louis,
MO), and wash of the isolated RNA in 70 % ethanol.
Then, 1 μg RNA was reverse-transcribed using the high-
capacity complementary (cDNA) reverse transcription
kit (Life Technologies). Real-time PCR amplification was
performed on the mixture of 100 ng cDNA sample,
Taqman Universal PCR Master Mix, and Taqman
Probes (Life Technologies) using the Applied Biosystems
Step One Plus Real-Time PCR System. Probes included
Arg1 (Mm00475988), CD206 (Mm00485148), and CD86
(Mm00444543). Expression of genes was normalized to
18S mRNA for each sample, and reported values were
calculated as 2-ΔΔCT relative to a sham reference sample.
Behavioral analysis
All experimental animals were assessed using the Basso
Mouse Scale (BMS) to score hindlimb function as previ-
ously described [23]. Mice were tested in an open field
for 4 min before surgery and at 1, 3, 7, 14, 21, and
28 days post injury (dpi). Each hindlimb was scored sep-
arately based on movement (e.g., ankle placement and
stepping), coordination, and trunk stability, and aver-
aging both hindlimb scores generated a single score for
each animal. A score of 0 indicated complete paralysis
and a score of 9 indicated normal locomotion. Assess-
ment of hindlimb function was also carried out using
the gridwalk test [24]. The gridwalk utilizes a horizontal
ladder with stainless steel rungs 4 mm in diameter
spaced 1.2 cm apart. All experimental mice were trained
before injury. On 27 dpi, only mice that could support
their own body weight were tested on the apparatus. An-
imals were videotaped and evaluated on 30 continuous
rungs on the center of the ladder. Frame-by-frame video
analysis was used to track the total number of hindlimb
steps/footfalls.
Tissue processing and immunohistochemistry
Mice were anesthetized and then transcardially perfused
with cold PBS (0.1 M, pH 7.4), followed by perfusion
with cold 4 % paraformaldehyde (PFA). Dissected spinal
cords (1 cm) were post-fixed for another 2 h in 4 % PFA
and subsequently rinsed and stored in cold phosphate
buffer (0.2 M, pH 7.4) overnight at 4 °C. On the following
day, tissues were cryoprotected in 30 % sucrose for 3 days
at 4 °C, followed by rapidly freezing and blocking in
optimal cutting temperature (OCT) compound (Sakura
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Finetek USA, Inc.) on dry ice. Tissue was systematically
randomized into blocks with equal group distribution to
ensure uniformity of staining across groups, and blocked
tissue was stored at −80 °C before sectioning. Tissue
blocks were cut in serial coronal sections (10 μm) and
mounted onto Colorfrost plus slides (Fisher #12-550-17).
Spinal cord sections were stained for glial fibrillary acidic
protein (GFAP) or neurofilament (NF) to measure tissue
sparing. Slides were incubated with chicken anti-GFAP
(1:200; Aves GFAP) or chicken anti-NF (1:1500, Aves NFH
0211) primary, followed by biotinylated goat anti-chicken
(1:1000; Aves B-1005) then Alexa Fluor 488 (1:1000; Invi-
trogen S32354) secondary antibodies. Slides were cover-
slipped with Immu-Mount (Thermo Scientific, Waltham,
MA). GFAP or NF fluorescent images were taken using a
C2+ laser scanning confocal microscope (Nikon Instru-
ments Inc., Melville, NY). To quantify spared tissue area,
the regions of dense GFAP- or NF-positive staining were
outlined and measured using the MetaMorph analysis pro-
gram (Molecular Devices, Sunnyvale, CA).
Cell culture
Bone marrow-derived macrophages (BMDMs) were ex-
tracted from the femur and tibia of female C57BL/6
mice at 8–10 weeks of age as previously reported
[25, 26] and were plated at 0.8 ~ 1 × 106 cells/ml in
differentiation media: Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 1 % penicillin/
streptomycin, 1 % HEPES, 0.001 % β-mercaptoethanol,
10 % FBS, and 20 % supernatant from sL929 cells (a gen-
erous gift from Phillip Popovich, The Ohio State Univer-
sity). Supernatant collected from sL929 cells contains
macrophage colony-stimulating factor, which helps to pro-
mote bone marrow cells’ differentiation into macrophages
[27]. The BMDMs were allowed to differentiate for 7 days
in culture, and cells were then replated on day 7 at a dens-
ity of 1 × 106 cells/ml in 12-well plates in differentiation
media without L929 supernatant. On day 8, cells were
stimulated to be M1 using LPS (50 ng/ml; Invivogen tlrl-
eblps) plus IFNγ (20 ng/ml; eBioscience 14-8311-63) di-
luted in N2A growth medium. AZM (10 or 30 μM; Sigma
PHR1088) or vehicle (DMSO; MP Biomedical 190186)
was added at the time of stimulation. Unstimulated
BMDMs were used as control. Six hours after incubation,
the supernatant of the stimulated macrophages (macro-
phage-conditioned media (MCM)) was collected, filtered,
then applied to cultured Neuro-2a cells or tested for IL-10
and IL-12p40 levels using standard ELISA kits (Thermo
Scientific, Rockford, IL).
Mouse neuroblastoma cell lines (aka Neuro-2a or N2A,
a gift from Chris Richards , University of Kentucky) were
maintained in N2A growth medium containing 45 %
DMEM, 45 % OPTI-MEM reduced-serum medium, 10 %
fetal bovine serum (FBS), and 1 % penicillin/streptomycin.
N2A were plated at a density of 1 × 105 cells/ml in 48-well
tissue culture plates and allowed to proliferate for 48 h.
The neurotoxicity of MCM was evaluated as reported pre-
viously [7] using a MTT-based cell growth determination
kit according to the manufacturer’s instructions (Sigma-al-
drich). Briefly, on the day of testing, N2A growth media
was replaced by fresh MCM, and the N2A cells were incu-
bated in MCM for 24 h then thiazolyl blue tetrazolium
bromide (MTT (5 mg/ml), 20 μl per well) was added to
each well and the cells further incubated for 2 h. The
tetrazolium ring of MTT can be cleaved by mitochondrial
dehydrogenases of viable cells, yielding purple formazan
crystals, which were then dissolved in acidified isopropa-
nol solvent. The resulting purple solution was spectro-
photometrically measured at 570 nm Epoch microplate
reader (BioTek instruments, Inc., Winooski, VT) using
690 nm as a background absorbance. All measurements
were done in triplicates, and at least three independent ex-
periments were carried out.
Statistical analysis
Investigators blinded to experimental conditions per-
formed all data acquisition and analysis. Statistical
analyses were completed using GraphPad Prism 6.0
(GraphPad Software). Data were analyzed using one-
or two-way ANOVA followed by Holm-Sidak’s test for
multiple comparisons. F-values are reported for repeated
measures. Chi square and independent sample t tests were
used when appropriate. Results were considered statisti-
cally significant at p ≤ 0.05. All data are presented as mean
± SEM unless otherwise noted. Figures were prepared
using Adobe Photoshop CS6 (Adobe Systems) and Prism
6.0.
Results
AZM alters the macrophage response to SCI
To determine the effects of AZM treatment on the in-
flammatory cell response to SCI, mice were treated daily
with AZM or vehicle beginning 3 days prior to 75-kdyn
T9 contusion SCI with continued daily administration
(oral gavage) up to 7 days post injury (dpi). There were
no significant differences between treatment groups in
spinal cord displacement at the time of SCI (p > 0.35 for
any given time point between groups and p = 0.50 for
overall group effect). This is an important control to en-
sure all animals received comparable SCI regardless of
pre-injury treatment. At 1, 3, or 7 dpi, cells were isolated
from the injured spinal cord for phenotypic analysis
(Fig. 1). Cells were labeled with antibodies specific for
neutrophils (Gr-1) and macrophages (CD11b/CD45) then
the relative numbers of neutrophils (CD11b+/CD45hi/
GR1hi) and monocyte- (CD11b+/CD45hi/GR1lo/neg) and
microglia- (CD11b+/CD45lo/GR1lo/neg) derived macro-
phages were quantified. As indicated in Fig. 1a, few
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Fig. 1 (See legend on next page.)
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monocyte-derived macrophages or neutrophils were
detectable 1 day after sham SCI (also see dotted line in
Fig 1c). Figures 1b, c show that the number of CD11b
+/CD45hi/GR1hi neutrophils in the injured spinal cord
peaked at 1 dpi then decreased over time, CD11b
+/CD45hi/GR1lo/neg monocyte-derived macrophage num-
bers remained elevated over time, and CD11b+/CD45lo/
GR1lo/neg microglia increased from 1 to 7 dpi. In addition,
AZM significantly attenuated the monocyte response to
SCI at 3 dpi (Fig 1c, p < 0.05).
Next, we determined the phenotype of SCI macro-
phages using FACS to purify CD11b+/CD45+/GR-1−
macrophages from the spinal cord homogenates (both
monocyte and microglia populations in Fig. 1b were
pooled). Messenger RNA (mRNA) was isolated from the
sorted, purified macrophages, and the relative gene
expression of M2, anti-inflammatory (arginase, CD206),
and M1, pro-inflammatory (CD86), macrophage markers
was determined. Figure 1d shows that the expression of
markers indicative of an anti-inflammatory phenotype,
arginase and CD206, increased with SCI and AZM treat-
ment significantly augmented expression of both arginase
(F1,12 = 23.13, p = 0.0004) and CD206 (F1,12 = 11.86, p =
0.005) (Fig. 1d). Expression of the pro-inflammatory
marker, CD86, increased with SCI and expression was at-
tenuated by AZM treatment (F1,12 = 25.91, p = 0.003).
There were no significant differences in macrophage
phenotype between AZM- or vehicle-treated animals at
28 dpi (p > 0.8 for CD86 and arginase expression;
Additional file 1: Figure S1).
Next, we examined if AZM was differentially increas-
ing M2 marker expression on different macrophage pop-
ulations. We used a CD206 antibody to determine the
M2 profiles of monocyte- (CD11b+/CD45hi/GR1lo/neg)
and microglia- (CD11b+/CD45lo/GR1lo/neg) derived mac-
rophages isolated from the injured spinal cord at 3 and
7 days post-injury. Similar to what has been reported
previously [6], microglia-derived macrophage expression
of this M2 marker decreased over time (Fig. 1e). There
was a significant time × drug interaction (F1,11 = 5.83,
p = 0.03) with AZM significantly increasing the number
of CD206+ microglia-derived macrophages relative to ve-
hicle controls at 3 dpi (Fig. 1e, p = 0.01). This effect was
not significant at 7 dpi (Fig. 1e, p > 0.6). In accordance
with what has been previously reported for monocyte-
derived macrophages [6], we observed similar levels of
CD206 expression at both time points. Specifically, the
numbers of CD206+ monocyte-derived macrophages were
similar at 3 and 7 dpi, and there were no significant differ-
ences between AZM and vehicle at either time point
(time × drug interaction (F1,11 = 0.28, p = 0.6)): 3 dpi,
mean ± SEM: 1914 ± 156 (AZM) and 1988 ± 255 (veh);
7 dpi, 1945 ± 207 (AZM) and 1800 ± 155 (veh).
Collectively, these results indicate that AZM treatment
alters the inflammatory response to SCI and decreases
pro-inflammatory macrophage gene expression while po-
tentiating anti-inflammatory macrophage gene expression.
Further, AZM may potentiate microglia- vs. monocyte-
derived M2 macrophage activation in response to SCI.
AZM treatment improves locomotor recovery and
decreases tissue pathology associated with SCI
Alterations in macrophage phenotypes are associated
with differences in functional recovery and tissue sparing
following SCI [6]. Because AZM treatment increased
indices of anti-inflammatory macrophage activation, we
assessed the ability of AZM treatment to improve SCI
recovery. Figure 2a–g shows that AZM treatment
resulted in significantly more spared tissue at 28 dpi.
Specifically, the rim of spared tissue, defined using positive
GFAP immunoreactivity, was roughly twofold greater fol-
lowing AZM (mean ± SEM= 0.25 ± 0.04 mm2) vs. vehicle
treatment (0.13 ± 0.02 mm2) (p = 0.01). The area of
neurofilament-positive spared axons was also significantly
improved with AZM (0.21 ± 0.05 mm2) vs. vehicle treat-
ment (0.098 ± 0.02 mm2) (p = 0.04).
Small differences in the amount of preserved tissue at
the lesion epicenter after SCI correlate with significant
differences in locomotor recovery [28]. To examine
functional recovery in response to AZM treatment, loco-
motor function was assessed using the Basso Mouse
Scale (BMS) [23]. As shown in Fig. 2h, following SCI,
(See figure on previous page.)
Fig. 1 AZM treatment increases alternative macrophage activation in mouse SCI. Animals were subjected to a moderate-severe T9 SCI and treated
with 160 mg/kg AZM or vehicle using a combined pre- (3 days) and post- (up to 7 days) SCI daily treatment regimen. a, b Scatter plots of
CD11b/CD45+ cells isolated from spinal cord homogenates after sham or contusion SCI. Cells were collected from 10 mm of spinal cord tissue
centered on the lesion epicenter. The specificity of the gates is evident as neutrophils and monocytes enter the spinal cord only after SCI (b). c
Quantification of neutrophils (CD11b+/CD45hi/GR1hi), monocyte-derived macrophages (CD11b+/CD45hi/GR1lo/neg), and microglia (CD11b+/CD45lo/
GR1lo/neg) (gates indicated in b) following vehicle or AZM treatment (1 dpi sham values indicated with dotted line). AZM significantly attenuated
monocyte recruitment to the spinal cord at 3 dpi (p = 0.03). d rtPCR of mRNA expression in FACS-sorted macrophages (combined monocyte and
microglia populations identified in b) reveal significant increases in gene expression for the M2 markers arginase 1 and CD206 in AZM vs. vehicle
controls (values relative to sham expression levels indicated with dotted line). The M1 marker, CD86, was significantly decreased with AZM treatment.
e Representative plots for microglia-derived macrophages (CD11b+/CD45lo/GR1lo/neg) showing labeling with CD206 primary antibody and
unstained controls. There is a significant increase in the number of CD206+ microglia-derived macrophages with AZM treatment. +p < 0.06, *p < 0.05,
**p < 0.01, ***p < 0.001; n = 3–5
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both treatment groups had significant functional deficits
that improved over time (F5,75 = 179.7, p < 0.0001).
There was significant overall treatment effect (F1,15 =
9.961, p = 0.007) and significant time × treatment inter-
action (F5,75 = 10.75, p < 0.001) meaning that AZM
treatment significantly improved both the rate of recov-
ery and overall level of residual deficits associated with
SCI (Fig. 2h). Specifically, significant improvements were
detected for AZM-treated mice compared to vehicle-
treated by 14 dpi. At 28 dpi, AZM-treated animals had
recovered consistent stepping (BMS ~ 5) while vehicle-
treated animals had some limb movement without
weight-supported stepping (BMS ~ 3). These improve-
ments were also reflected in the BMS subscore, a sup-
plement to the BMS scale that is sensitive to treatment-
specific recovery progressions that may fall outside the
normal pattern of recovery [23]. Specifically, there was a
main effect of treatment (F1,15 = 10.93, p = 0.005) and
time × treatment interaction (F5,75 = 11.76, p < 0.0001)
that manifested at 28 dpi as fore-hindlimb coordination
Fig. 2 AZM treatment improves tissue sparing and recovery in SCI mice. Tissue sections representative of the mean values for vehicle- (a–c) and
AZM- (d–f) treated animals at 28 dpi. a, d Inverted fluorescent images of GFAP-stained tissue sections of the lesion epicenter. b, e Adjacent sections
stained with neurofilament (NF) indicate that areas of GFAP immunoreactivity correspond to areas of spared axons. c, f Higher powered confocal
images of the rim of spared tissue reveal increased axon preservation with AZM treatment. g Quantification of tissue sparing at the lesion epicenter
based upon GFAP immunoreactivity (*p = 0.01). h–i Functional recovery was assessed over a 28-day period using the Basso Mouse Scale (BMS). Mice
treated with AZM recovered consistent stepping (BMS ~ 5) and coordination (BMS subscore ~4); vehicle-treated animals had some limb movement
(BMS ~ 3) without coordination (BMS subscore = 0). j A significantly higher proportion of mice treated with AZM regained coordination of fore and
hindlimbs compared to vehicle treated. *p < 0.05 vs. vehicle, **p < 0.01 vs. vehicle for each individual time point according to post hoc comparisons in
response to the significant main treatment effect (p = 0.007). n = 8–10. Scale bar = 100 μm for a, b, d, e and 416 μm for c, f
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in the AZM group (BMS subscore ~4) with no fore-
hindlimb coordination in the vehicle-treated group
(BMS subscore ~0) (Fig. 2i).
Coordination is an important aspect of SCI recovery;
therefore, we used a variety of motor tasks to determine
if AZM treatment facilitated recovery of coordinated
and proprioceptive function. First, a BMS score of 5 can
indicate some level of coordination between fore- and
hindlimb movements [23]. Figure 2 shows that all but
one animal in the AZM-treated group achieved this
score while only one animal in the vehicle group
achieved coordination by 28 dpi (p = 0.002) (Fig. 2j).
Next, we assessed animals on the gridwalk task at
27 dpi. The gridwalk is a horizontal ladder task that
measures sensory-motor coordination [29]. Two animals
from the AZM group and three animals from the vehicle
group did not achieve a sufficient level of recovery for
gridwalk testing. Figure 3 shows that of animals able to
perform the task, those treated with AZM had ~40 %
fewer footfalls compared to vehicle-treated (p = 0.05).
Overall, AZM treatment improved the locomotor function
and coordination of mice recovering for contusion SCI.
AZM alters the neurotoxicity of pro-inflammatory
macrophages
Because we previously observed that pro-inflammatory
macrophages are neurotoxic and likely potentiate second-
ary injury processes while anti-inflammatory macrophages
do not cause cell death and drive repair processes [3], we
next sought to determine if these neuroprotective effects
could be mediated through AZM altering the toxic poten-
tial of pro-inflammatory macrophages.
The effects of stimulating bone marrow-derived mac-
rophages (BMDMs) in vitro are predictive of spinal cord
macrophage responses in vivo [25, 26, 30]. Therefore, we
examined the phenotype and neurotoxic potential of
pro-inflammatory BMDMs treated with AZM in vitro.
We used LPS + INFγ stimulation to model the pro-
inflammatory, M1, macrophages that are activated in
SCI [3, 6]. Figure 4a shows that AZM drives increased
production of IL-10, an anti-inflammatory cytokine,
while reducing pro-inflammatory IL-12 release from M1
macrophages. In the absence of the pro-inflammatory
stimuli, AZM had no effect on unstimulated BMDMs
(Fig. 4a). An increased ratio of IL-10:IL-12 is a defining
feature of anti-inflammatory macrophages; therefore,
we conclude from Fig. 4a that AZM drives pro-in-
flammatory macrophages toward an anti-inflammatory
phenotype. As shown in Fig. 4b, this shift was associated
with a significant decrease in the neurotoxicity of pro-
inflammatory macrophages. Specifically, BMDMs were
stimulated to be M1 in the presence or absence of AZM.
The supernatants from these cells, deemed macrophage-
conditioned media (MCM), were collected and used to
treat neurons. The MCM from M1 cells resulted in
significant reduction (~30 %, p = 0.001) in neuron
viability relative to MCM from untreated cells. This
toxicity was significantly attenuated with AZM treat-
ment, as there was no significant difference in viabil-
ity among neuron groups exposed to MCM from
untreated vs. M1 + AZM-treated BMDMs (p > 0.15;
Fig. 4b) or untreated vs. AZM-treated in the absence
of M1 stimuli (p > 0.20; Fig. 4b). The results presented
in Fig. 4 are representative of three independent
experiments. Collectively, these results demonstrate
that AZM can act directly on macrophages to alter
pro-inflammatory activation and reduce macrophage-
mediated neurotoxicity.
Fig. 3 AZM treatment improves coordinated proprioceptive locomotor function in SCI mice. At 28 dpi, animals were tested on the gridwalk for
proprioceptive coordination. a–b Frame-by-frame video analysis was used to track hindlimb steps/footfalls (graphically represented as ovals).
c AZM-treated animals had significantly less footfalls than vehicle (p = 0.05; scored over 30 rungs). d Graphical representation of the footfall/stepping
patterns over 11 rungs for one animal from each group representative of the mean performance of each group (n = 6–7)
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Discussion
There is growing evidence that altering the phenotype of
macrophages responding to SCI can improve recovery.
Despite this, few safe pharmacological approaches have
been identified that can manipulate SCI macrophages.
Here, we show that in a mouse model, treatment with
the macrolide antibiotic, AZM, results in increased
macrophage expression of anti-inflammatory genes and
facilitates significant improvements in SCI locomotor re-
covery and tissue sparing. Macrophages, purified from the
injured spinal cord of mice treated with AZM, had in-
creased expression of CD206 and arginase, indicators of
an anti-inflammatory phenotype, with decreased expres-
sion of the pro-inflammatory marker CD86 (Fig. 1). AZM
treatment significantly improved locomotor function com-
pared to vehicle control, specifically in indices of loco-
motor coordination (Figs. 2 and 3). The improvements in
locomotor recovery were associated with significant in-
creases in tissue sparing (Fig. 2), presumably due to AZM
reducing the neurotoxic potential of SCI-activated macro-
phages. Indeed, in vitro, AZM drove pro-inflammatory
macrophages toward an anti-inflammatory phenotype
with reduced neurotoxic properties (Fig. 4). Collectively,
these data highlight the potential for an immunomodula-
tory, pharmacological therapy to be an effective treatment
for SCI and identify AZM as a promising candidate for
further translational development.
These key findings are consistent with observations of
AZM-mediated changes in macrophage phenotype in
models of lung infection, skin inflammation, and sepsis
[17, 19, 31]; however, the results reported here are the
first to document that AZM can have a similar effect
after traumatic CNS injury. While pro-inflammatory
macrophage activation is reduced with AZM treatment
in acute conjunctiva [32], to the best of our knowledge,
the current results are the first to demonstrate that
AZM, or any other macrolide antibiotic, alters macro-
phage phenotype in response to spinal cord injury and
reduces macrophage neurotoxicity. This is significant as
neuroinflammation, and specifically pro-inflammatory
macrophage activation, is a common feature of most
neuropathological conditions including Alzheimer’s
disease, stroke, aging, ALS, and traumatic brain injury
[33–36]. The ability of AZM to be widely distributed
in brain tissue following oral administration [37] makes it
an intriguing candidate for manipulating macrophages in
a variety of nervous system pathologies.
There is extensive data regarding the safety and dosing
of AZM. Specifically, AZM is one of the antibiotics of
choice for treating pneumonia in SCI individuals and is
routinely administered at 10–45 mg/kg/day to treat
infections in humans including community-acquired
pneumonia, otitis media, and sinusitis [12, 13, 38]. Ac-
counting for allometric scaling, the dose of 160 mg/kg
used in the current study is high but still clinically rele-
vant, especially considering that higher AZM doses
should be tolerated if necessary for neuroprotection due
to the drug’s large therapeutic window and limited toxicity
profile. Additionally, the recent results of the “COPD:
influence of macrolides on exacerbation frequency in
patients” (COLUMBUS) clinical trial report that AZM can
be administered chronically (for 12 months), albeit at
lower doses, with maintained immunomodulatory effects
and no increased adverse effects [39]. Ongoing work in
Fig. 4 AZM treatment alters the phenotype and toxic potential of pro-inflammatory, M1 macrophages in vitro. Bone marrow-derived macrophages
(BMDMs) were isolated from adult mice and stimulated to be M1 using LPS + INFγ in the presence or absence of AZM. Control cells were unstimulated
or stimulated with AZM alone. a A high ratio of IL-12:IL-10 is a defining feature of M1 macrophages. AZM significantly decreased M1 production of the
pro-inflammatory cytokine IL-12 and increased production of the anti-inflammatory cytokine IL-10. AZM alone had no affect on cytokine production. b
MCM from M1 macrophages stimulated with AZM was not toxic to neurons. AZM alone did not significantly affect BMDM neurotoxicity (p > 0.2 for
either AZM dose vs. Unstim). Data are representative of three independent replications. *p < 0.05, **p < 0.01 vs. M1. ***p < 0.001 vs. unstim and p < 0.05
vs. M1 + AZM groups. Mean ± SD
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our lab is examining the effect of lower doses of AZM on
SCI inflammation and recovery.
One major limitation of the current work regarding
the effectiveness of AZM for SCI treatment is that we
utilize a combined pre- and post-SCI dosing strategy.
We used this approach, based upon a previous dosing
strategy we found to be effective for reducing inflamma-
tory damage associated with acute lung infection [17], to
test the proof-of-concept that AZM can effectively alter
inflammation in response to CNS perturbations. Indeed,
our findings provide evidence that initiating treatment
prior to CNS inflammation is effective. This approach
may be beneficial for altering inflammation in chronic
neurodegenerative disease, e.g., aging and Alzheimer’s.
This is especially relevant in light of the effectiveness of
chronic AZM administration reported in the COLUM-
BUS study [39] and our previous observations that AZM
treatment produces similar immunomodulary changes in
both rodents and humans [17, 40]. We have made prelim-
inary observations that AZM is effective when administra-
tion begins after SCI (unpublished data, manuscript in
preparation). In addition, in the current study, AZM had
no effect on macrophage phenotype in the absence of an
inflammatory stimulus in vitro (Fig. 4). This is consistent
with our previous observations, and that of others, that
AZM does not polarize unstimulated macrophages [41].
Collectively, we therefore postulate that AZM treatment
prior to SCI may not be required to facilitate improve-
ments; however, additional studies are required to deter-
mine the therapeutic potential and required dosing for
effective post-injury AZM treatment of SCI.
One observation in this study was that AZM treat-
ment decreased monocyte-derived macrophages in the
injured spinal cord. This is consistent with observations
of reduced inflammation and macrophage accumulation
with AZM treatment in models of acute conjunctiva,
lung infection, and skin inflammation [17, 19, 32]. In
addition, decreasing macrophage accumulation at the
site of SCI is neuroprotective and facilitates recovery
[42]. However, the mechanisms underlying the decreased
macrophage recruitment we observed remain to be
elucidated, as do the effects of AZM on monocyte- vs.
microglia-derived macrophages.
Evidence that altering macrophage phenotypes or redu-
cing M1 macrophage activation in SCI can be therapeutic
comes from recent publications demonstrating that de-
creasing M1 macrophages in transgenic models of SCI
leads to improved recovery, decreasing M2 macrophages
or increasing M1 macrophages impairs SCI recovery, and
increasing M2 macrophages using viral or transplantation
approaches correlates with improvements in recovery
[5, 6, 9, 43–45]. Our data demonstrate that the
underlying mechanism mediating improvements in
SCI recovery with AZM treatment may be due to its
ability to reduce the neurotoxic potential and pro-
inflammatory activation state of SCI macrophages. We
have previously observed an M1 to M2 macrophage shift
with AZM treatment in vitro [14]. The concept that AZM
can shift macrophage phenotype is further supported by
independent publications noting decreased IL-12, IL-6,
IL-1β, TNF-α, and other pro-inflammatory mediators
when macrophages are stimulated in the presence of
AZM [15, 21, 46–49]. Interestingly, these publications
suggest that M1, but not M2, macrophage activation is af-
fected by AZM. It is also possible, given the combined
pre-and post-SCI dosing strategy, that AZM prevented
M1 polarization in the current study rather than altering
the M1 to M2 phenotype. This concept is support by the
observation that AZM inhibits signaling cascades specific
to pro-inflammatory stimuli [50]. The specific mechanism
responsible for the immunomodulatory potential of
AZM and other macrolides are not well understood.
Nonetheless, these collective observations indicate
that AZM may selectively attenuate pro-inflammatory
macrophage activation.
The neuroprotective effects we report with AZM are
similar to the effects reported for SCI treatment with the
antibiotic minocycline [51]. Identifying neuroprotective,
non-minocycline antibiotics has important implications
for SCI therapeutic translation and treatment. There is
an inherent risk of developing antimicrobial resistance
with any antibiotic use, especially in SCI individuals who
often undergo repeated antibiotic treatments to fight re-
current infections [13, 52]. In addition, higher adverse
reaction rates are associated with minocycline vs. other
antibiotic treatments [53]. Therefore, the identification
of neuroprotective and antibiotic alternatives to minocy-
cline increases the probability that these drugs can be
used as neuroprotective strategies for treating SCI.
It is also important to identify the immunomodulatory
mechanism of actions in order to develop more potent
neuroprotectants. Due to structure differences between
tetracycline (minocycline) and macrolide (azithromycin)
antibiotics, it is difficult to imagine that both antibiotics
are working through similar mechanisms of action.
Attenuated pro-inflammatory microglial activation, how-
ever, has been reported with minocycline treatment in
vitro [54]. Interestingly, similar to AZM, minocycline se-
lectively affects M1 but not M2 macrophages. Inhibition of
the NF-κB pathway in pro-inflammatory macrophages has
been observed for both antibiotics [41, 54]. In addition, this
is a somewhat common feature of other macrolide
antibiotics [50]. It is worth investigating the common
structural elements of macrolides, and potentially other
antibiotics, that mediate these immunomodulatory effects.
Identifying the necessary structural components of
macrolides that effect macrophage biology would provide
insight into pro-inflammatory macrophage activation
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while facilitating development of more potent therapies
that do not have the potential for causing antimicrobial re-
sistance. There is evidence that modified macrolides retain
their immunomodulatory properties [55–58], and we are
currently exploring the ability to use these or other novel
macrolide compounds to facilitate CNS repair.
We recently reviewed the potential positive impact of
M2 macrophages on SCI wound repair [2]. Moving for-
ward, it is important to determine mechanistically
whether the benefits observed in SCI through AZM treat-
ment are due primarily to the reduction of inflammatory
factors and M1 macrophage activity or if there is a specific
beneficial function of the M2 macrophage that AZM po-
tentiates. A more regulatory battery of cytokine produc-
tion, including IL-10 and TFGβ, is typical with M2 cells
[59, 60]. In addition, M2 macrophages can actively inhibit
inflammatory processes through arginase-1 up-regulation,
which competes with inducible nitric oxide synthase
(iNOS) for L-arginine [61, 62]. These studies demonstrate
the ability of M2 macrophages to suppress iNOS produc-
tion, reduce inflammatory cytokine/chemokine secretion,
and control neutrophil infiltration [63]. However, in our
own studies of cystic fibrosis patients, we observed that
chronic AZM treatment significantly lowered inflamma-
tory gene expression including iNOS and TNF-α, but did
not significantly increase M2-associated gene expression
[40]. The future goal of our studies is to characterize the
complicated role of anti-inflammatory macrophages over
the entire post-injury time course.
Conclusions
The findings presented here demonstrate that AZM can
alter the macrophage response to SCI and facilitate im-
prove tissue sparing and functional recovery. We also
demonstrate that AZM directly alters the phenotype and
neurotoxic potential of pro-inflammatory macrophages
in vitro. AZM is safe at high doses, can be administered
chronically without adverse effects, and accumulates in
brain tissue following oral administration. These features
make AZM an ideal drug for treating neuroinflammatory
conditions. Additional studies are needed to determine
the effectiveness of post-injury administration, optimize
the dose and therapeutic window for SCI, and examine
the mechanisms through which AZM alters inflammation.
Our data in mice, nonetheless, indicate that AZM is a
promising therapy for treating SCI.
Additional file
Additional file 1: Figure S1. AZM treatment does not lead to long-term
changes in macrophage activation or phenotype after SCI. Representative
tissue sections of vehicle- (A, D, F) and AZM- (B, E, H) treated animals at
28 dpi. A, B Fluorescent images of Tomato Lectin (TomL)-stained sections
(1:1000, Cat# L0651, Sigma-Aldrich) reveal no significant difference in the
density of macrophage activation between groups as quantified in C.
(Note for C, F, and I, proportional area was quantified and normalized to
vehicle). D, E Fluorescent images of the same sections as A, B stained for
CD86 (1:100, Cat# 553689, BD Pharmingen, Franklin) show no differences
between groups as quantified in F. G, H Fluorescent images of the adjacent
sections to A,B/D,E stained for arginase 1 (1:200, Cat # sc-18354, Santa Cruz
Biotech) show no difference between groups as quantified in I. Scale
bar = 100 μm, n = 8–10.
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